Will pharma M&A keep up the pace in second half of 2019?

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Martin Barraud)
(Image: Getty/Martin Barraud)

Related tags Celgene Bristol-myers squibb Eli lilly AbbVie Allergan Pfizer Mylan

So far in 2019, there has been significant activity in M&A, particularly on the larger scale, but can the pace continue for the rest of the year?

The year began with a bang, with Bristol-Myers Squibb lining up a $74bn (€65.2bn) acquisition of Celgene​ – in the largest deal the pharmaceutical industry had seen, though it was not without its controversy​.

Closely following on the heels of this deal was the announcement that Eli Lilly would spend $8bn on Loxo Oncology​, gaining access to the latter’s pipeline of targeted treatments for single gene disorders.

Following these two announcements, a further two deals of similar significance were announced in the summer months: AbbVie’s $63bn deal for Allergan​ and Pfizer’s tie up with Mylan for the creation of a new pharmaceutical company​.

The question remains whether the pace and scale of M&A for the latter half of 2019 will continue towards the end of the year.

Here’s an opportunity to have your say:

Will pharma M&A continue at the same pace for the rest of the year?
I expect more deals in the second half.

Related news

Show more